Overview

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
To evaluate the long-term safety and tolerability of oral dersimelagon.
Phase:
Phase 3
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Development America, Inc.